Recordati Aktie - REC

Professionelle Tools für Privatanleger.

Premium

Current Price

52,70

Gebot

52,20

Fragen

53,10

Volumen

307.523

52,30 Tagesbereich 52,95

47,28 52-Wochen-Bereich 60,50

Marktkapitalisierung

10,822B

Handelsende

52,95

Handelsbeginn

52,90

Letzte Trade

182

52.7

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

403.695

Ausgegebene Aktien

205.358.104

Dividendenrendite

2.33%

Kurs-Gewinn-Verhältnis

29,30

Gewinn pro Aktie (EPS)

1,9

Erlöse

2,07B

Nettogewinn

389,21M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.recordati.it

Hauptsitz

Milan, Lombardy, Ita

Gegründet

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italienische Börse with ticker REC. The last closing price for Recordati was 52,95 €. Over the last year, Recordati shares have traded in a share price range of 47,28 € to 60,50 €.

Recordati currently has 205.358.104 shares in issue. The market capitalisation of Recordati is 10,87 € billion. Recordati has a price to earnings ratio (PE ratio) of 29.30.

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès ann...

Les résultats significatifs de l’étude pivot LINC 4 de Phase III démontrent qu’Isturisa® (osilodrostat) permet une normalisation rapide et...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.65	-1.21836925961	53.35	54.55	52.15	488147	53.0473325	DE
4	-7.05	-11.7991631799	59.75	60.3	52.15	603861	54.6635603	DE
12	2.65	5.29470529471	50.05	60.5	49.16	403695	55.08055637	DE
26	2	3.94477317554	50.7	60.5	48.58	327135	53.52664008	DE
52	-0.44	-0.828001505457	53.14	60.5	47.28	279631	52.10238048	DE
156	9.05	20.7331042383	43.65	60.5	34.52	245133	46.53274656	DE
260	19.94	60.8669108669	32.76	60.5	31.1	277639	46.1258184	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 52,70 €

How many Recordati shares are in issue?

Recordati has 205.358.104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 10,87B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 47,28 € to 60,50 € during the past year

What is the PE ratio of Recordati?

The price to earnings ratio of Recordati is 29,3

What is the cash to sales ratio of Recordati?

The cash to sales ratio of Recordati is 5,52

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2,07B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 389,21M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
MPTImpianti SpA	0,99 € (21,47%)	568,5k
1LEVILevi Strauss & Co	17,68 € (15,44%)	6
WFCT26Fincantieri SpA	0,9201 € (14,30%)	2,03M
1AAGAumann AG	11,66 € (12,33%)	70
SESSesa SPA	77,95 € (10,88%)	130,3k
WSAC25Saccheria Flli Franceschetti SpA	0,01 € (-50,00%)	4k
WAMB26Ambromobiliare SpA	0,028 € (-29,82%)	36,9k
WPSQ26Pasquarelli Auto SpA	0,0071 € (-29,00%)	110k
AURNB Aurora SA SicafRaif	10,00 € (-26,50%)	7,9k
ELNElEn SpA	9,47 € (-15,22%)	881,82k
TITTelecom Italia SpA	0,2961 € (5,86%)	700,09M
TITRTelecom Italia	0,3291 € (4,24%)	81,11M
ISPIntesa Sanpaolo Spa	4,792 € (1,55%)	59,37M
SPMSaipem Spa	2,066 € (2,73%)	36,6M
ENELEnel Spa	7,016 € (0,30%)	33,93M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Recordati SpA (REC)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Recordati SpA

REC Neueste Nachrichten

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès ann...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Recordati SpA (REC) Börsenkurse

Recordati SpA (REC)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Recordati SpA

REC Neueste Nachrichten

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès ann...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen